Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130509 | 0.93 | SLC6A4 (0.56) | SLC6A4LMNAMAPK1ACHE | |
| SCHEMBL3408176 | 0.93 | SLC6A4 (0.56) | SLC6A4LMNAMAPK1ACHE | |
| SCHEMBL468540 | 0.93 | SLC6A4 (0.50) | SLC6A4LMNAMAPK1ACHE | |
| SCHEMBL3406618 | 0.92 | SLC6A4 (0.61) | SLC6A4LMNAMAPK1ACHE | |
| SCHEMBL3407342 | 0.92 | SLC6A4 (0.58) | SLC6A4LMNAMAPK1ACHE | |
| Hydrochloric Acid SCHEMBL6167023 | 0.92 | SLC6A4 (0.49) | SLC6A4LMNAMAPK1ACHE | |
| Hydrochloric Acid SCHEMBL6169234 | 0.91 | SLC6A4 (0.57) | SLC6A4LMNAMAPK1ACHE | |
| SCHEMBL3407874 | 0.90 | ACHE (0.49) | SLC6A4LMNAMAPK1ACHE | |
| SCHEMBL3404814 | 0.89 | SLC6A4 (0.52) | SLC6A4LMNAMAPK1ACHE | |
| SCHEMBL30130448 | 0.89 | SLC6A4 (0.52) | SLC6A4LMNAMAPK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | H. LUNDBECK A/S (DK) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | SLC6A4, SLC6A7, SLC6A5 | SLC6A4 1/4885LMNA 3677/4885MAPK1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.